
Product Data Sheet

Product Name: KY-02327

Cat. No.: GC63465

Chemical Properties

Cas. No. 2093407-25-9

Formula $C_{20}H_{27}N_3O_4$ M.Wt 373.45

Solubility DMSO : 100 mg/mL (267.77 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

KY-02327, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 shows an activating effect on the Wnt/ β -catenin pathway, resulting in promotion of osteoblast differentiation[1].

KY-02327 (1-10 μ M; 2 days; MC3T3E1 cells, a murine pre-osteoblast cell line) increases β -catenin protein level together with Runx2 and accumulated nuclear β -catenin in a dose-dependent manner[1]. KY-02327 (1-10 μ M) increases the mRNA levels of osteoblast differentiation markers collagen 1a (Col1a) and osteocalcin (OCN)[1].

KY-02327 (20 mg/kg; p.o.; 5 sequential days per week for 4 weeks) successfully rescues bone loss in the ovariectomized (OVX) mouse model[1].

[1]. Kim HY, et al. Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Mol Med. 2016;8(4):375-387.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA